Companies Dominating the Immune Repertoire Sequencing Market
- Agilent Technologies, Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Illumina, Inc.
- Pacific Biosciences of California, Inc
- QIAGEN N.V.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche AG
- Takara Bio, Inc
- Oxford Nanopore Technologies, Ltd
- BGI Group
- Atreca Inc
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of immune repertoire sequencing is assessed at USD 1.36 billion.
The immune repertoire sequencing market size was valued at USD 1.22 billion in 2024 and is expected to reach USD 2.87 billion by 2037, expanding at around 6.8% CAGR during the forecast period i.e., between 2025-2037. The market growth is propelled by increasing number of launches of novel products, and rising government funding to improve the healthcare infrastructure.
North America industry is set to hold largest revenue share by 2037, due to high health spending, and strong presence of market players in the region.
The major players in the market are Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Takara Bio, Inc, Oxford Nanopore Technologies, Ltd, BGI Group, Atreca Inc
